Ipsen Executive Management | Leading Innovation and Growth
Skip to main content
Ipsen Home Page
Press shift tab to select search category

Loading...
  • Media  arrow down
    < Back
    • Press Releases
    • Media Statements
    • Media Library
    • Our 2023 Integrated Annual Report is live!

      Featured Image
  • Investors arrow down
      < Back
    • Investors
    • Investors
    • Financial Results
    • Annual Reports and Accounts
    • Corporate News
    • Financial Calendar
    • Investor Events
    • Shareholder Information
    • Regulated Information
    • Key Contacts
  • Partnering
  • Careers arrow down
      < Back
    • Careers
    • Careers
    • Working at Ipsen
    • Culture
  • Press shift tab to select search category

    Loading...
  • English  EN     Français  FR     EN  arrow_down
    • English EN
    • Français FR
  • Global Global
    < Back
    • Global EN FR
    • Annual Report EN FR
    • Americas
    • Asia Pacific
    • Europe
    • United States
    • Brazil
    • Canada
    • Mexico
    • Australia
    • China
    • Singapore
    • South Korea
    • Japan
    • Belgium
    • Ukraine
    • UK
    • Germany
    • France
    • Nordics
    • Greece
    • Italy
    • Netherlands
    • Spain
    • Poland
    • Russia
    • Czech Republic
    • Switzerland
    • Austria
  • Home
  • Companyarrow down
      < Back
    • Company
    • Company
    • Leadership
    • History
    • Fondation Ipsen
  • Sciencearrow down
      < Back
    • Science
    • Science
    • Oncology
    • Rare Disease
    • Neuroscience
    • Products
    • R&D
    • Pipeline
    • Clinical Trials
    • Lay Summaries
  • Sustainabilityarrow down
      < Back
    • Sustainability
    • Sustainability
    • Environment
    • Patients
    • People
    • Governance
    • Our Standards
  • Patientsarrow down
      < Back
    • Patients
    • Patients
    • Together for Oncology
    • Together for Rare Disease
    • Together for Neuroscience
    • Collaborate with us
  • Stories

Executive Leadership Team

Ipsen’s Executive Leadership Team is composed of the Chief Executive Officer and 13 executive members.

David Loew

David Loew

Chief Executive Officer

Bartek Bednarz

Bartek Bednarz

Executive Vice President

Head of Global Product and Portfolio Strategy

Olivia Brown

Olivia Brown

Executive Vice President

Global Head of Neurotoxins

Josep Catllà

Josep Catllà

Executive Vice President

Chief Corporate Affairs Officer

Keira Driansky

Keira Driansky

Executive Vice President

President of North America

François Garnier

François Garnier

Executive Vice President

General Counsel

Christelle Huguet

Christelle Huguet

Executive Vice President

Head of R&D

Aymeric Le Chatelier

Aymeric Le Chatelier

Executive Vice President

Chief Financial Officer

Philippe Lopes-Fernandes

Philippe Lopes-Fernandes

Executive Vice President

Chief Business Officer

Régis Mulot

Régis Mulot

Executive Vice President

Chief Human Resources Officer

Aidan Murphy, Ph.D.

Aidan Murphy, Ph.D.

Executive Vice President

Head of Technical Operations

Laura Réveillon

Laura Réveillon

Executive Vice President

Strategy & Transformation

Mari Scheiffele

Mari Scheiffele

Executive Vice President

President, International

Sandra Silvestri, M.D., Ph.D.

Sandra Silvestri, M.D., Ph.D.

Executive Vice President

Chief Medical Officer

IPN price

€101.50

 €-0.40 (-0.39%)

  • Media
  • Investors
  • Partnering
  • Careers
  • Company
  • Sustainability
  • Patients
  • Stories
  • Annual Report
  • Contact us

Latest_Ipsen logo
LinkedIn Facebook Instagram Youtube
  • Terms and Conditions
  • Cookie Policy
  • Global Privacy Policy

© Ipsen Pharma. All rights reserved - 2025

You are now leaving the Ipsen group website. To continue, please click on Continue?

Continue